NSCLC metastatic/no molecular target
Ongoing protocols: click on the protocol for the inclusion and exclusion criteria (update 5/12/2018)
1st line
ELEVATION (Novartis)
Phase Ib, multicenter, open label study of PDR001 in combination with platinum-doublet chemotherapy in PD-L1 unselected, metastatic NSCLC patients.
(only cohort squamous NSCLC)
BFAST (Roche)
A phase II/III multicentre study evaluating the efficacy and safety of multiple targeted therapies as treatments for patients with advanced or metastatic non-small cell lung cance (NSCLC) harbouring actionable somatic mutations detected in blood (B-Fast: blood-first assay screening trial) (only squamous NSCLC)
IPSOS (Roche)
A phase III, open-label, multicenter, randomized study to investigate the efficacy and safety of atezolizumab compared with chemotherapy in patients with treatment-naïve advanced or recurrent (stage IIIB not amenable for multimodality treatment) or metastatic (stage IV) non-small cell lung cancer who are deemed unsuitable for platinum-containing therapy.
RO6874281 (Roche)
An open-label, multicentre, phase II study to evaluate the therapeutic activity of RO6874281, an immunocytokine, consisting of interleukin-2 variant (IL-2V) targeting fibroblast activation protein-A (FAP), in combination with atezolizumab (anti-PD-L1), administered intravenously, in participants with advanced and/or metastatic sold tumors. (only cohort E)
2th line
RO6874281 (Roche)
An open-label, multicentre, phase II study to evaluate the therapeutic activity of RO6874281, an immunocytokine, consisting of interleukin-2 variant (IL-2V) targeting fibroblast activation protein-A (FAP), in combination with atezolizumab (anti-PD-L1), administered intravenously, in participants with advanced and/or metastatic sold tumors. (only cohort F)
CAPMATINIB / SPARTALIZUMAB (Novartis)
A phase II, multicenter, randomized, two-arm study of capmatinib (INC280, an oral MET inhibitor) and spartalizumab (PDR001, a PD-1 inhibitor) combination therapy versus docetaxel in pretreated adult patients with EGFR wild-type, ALK rearrangement negative locally advanced/metastatic non-small cell lung cancer (currently Run-in period)
3th line
CAPMATINIB / SPARTALIZUMAB (Novartis)
A phase II, multicenter, randomized, two-arm study of capmatinib (INC280, an oral MET inhibitor) and spartalizumab (PDR001, a PD-1 inhibitor) combination therapy versus docetaxel in pretreated adult patients with EGFR wild-type, ALK rearrangement negative locally advanced/metastatic non-small cell lung cancer (currently Run-in period)
4th line
RO6874281 (Roche)
An open-label, multicentre, phase II study to evaluate the therapeutic activity of RO6874281, an immunocytokine, consisting of interleukin-2 variant (IL-2V) targeting fibroblast activation protein-A (FAP), in combination with atezolizumab (anti-PD-L1), administered intravenously, in participants with advanced and/or metastatic sold tumors. (only cohort D)
1st line
ELEVATION (Novartis)
Phase Ib, multicenter, open label study of PDR001 in combination with platinum-doublet chemotherapy in PD-L1 unselected, metastatic NSCLC patients.
(only cohort squamous NSCLC)
BFAST (Roche)
A phase II/III multicentre study evaluating the efficacy and safety of multiple targeted therapies as treatments for patients with advanced or metastatic non-small cell lung cance (NSCLC) harbouring actionable somatic mutations detected in blood (B-Fast: blood-first assay screening trial) (only squamous NSCLC)
IPSOS (Roche)
A phase III, open-label, multicenter, randomized study to investigate the efficacy and safety of atezolizumab compared with chemotherapy in patients with treatment-naïve advanced or recurrent (stage IIIB not amenable for multimodality treatment) or metastatic (stage IV) non-small cell lung cancer who are deemed unsuitable for platinum-containing therapy.
RO6874281 (Roche)
An open-label, multicentre, phase II study to evaluate the therapeutic activity of RO6874281, an immunocytokine, consisting of interleukin-2 variant (IL-2V) targeting fibroblast activation protein-A (FAP), in combination with atezolizumab (anti-PD-L1), administered intravenously, in participants with advanced and/or metastatic sold tumors. (only cohort E)
2th line
RO6874281 (Roche)
An open-label, multicentre, phase II study to evaluate the therapeutic activity of RO6874281, an immunocytokine, consisting of interleukin-2 variant (IL-2V) targeting fibroblast activation protein-A (FAP), in combination with atezolizumab (anti-PD-L1), administered intravenously, in participants with advanced and/or metastatic sold tumors. (only cohort F)
CAPMATINIB / SPARTALIZUMAB (Novartis)
A phase II, multicenter, randomized, two-arm study of capmatinib (INC280, an oral MET inhibitor) and spartalizumab (PDR001, a PD-1 inhibitor) combination therapy versus docetaxel in pretreated adult patients with EGFR wild-type, ALK rearrangement negative locally advanced/metastatic non-small cell lung cancer (currently Run-in period)
3th line
CAPMATINIB / SPARTALIZUMAB (Novartis)
A phase II, multicenter, randomized, two-arm study of capmatinib (INC280, an oral MET inhibitor) and spartalizumab (PDR001, a PD-1 inhibitor) combination therapy versus docetaxel in pretreated adult patients with EGFR wild-type, ALK rearrangement negative locally advanced/metastatic non-small cell lung cancer (currently Run-in period)
4th line
RO6874281 (Roche)
An open-label, multicentre, phase II study to evaluate the therapeutic activity of RO6874281, an immunocytokine, consisting of interleukin-2 variant (IL-2V) targeting fibroblast activation protein-A (FAP), in combination with atezolizumab (anti-PD-L1), administered intravenously, in participants with advanced and/or metastatic sold tumors. (only cohort D)
New trial in start-up:
- M7824 versus Pembrolizumab in 1st line (expected January 2019)